CA2832123C - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts - Google Patents

Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts Download PDF

Info

Publication number
CA2832123C
CA2832123C CA2832123A CA2832123A CA2832123C CA 2832123 C CA2832123 C CA 2832123C CA 2832123 A CA2832123 A CA 2832123A CA 2832123 A CA2832123 A CA 2832123A CA 2832123 C CA2832123 C CA 2832123C
Authority
CA
Canada
Prior art keywords
formula
dihydrochloride salt
mixture
cancer
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2832123A
Other languages
English (en)
French (fr)
Other versions
CA2832123A1 (en
Inventor
Jan Georg Peters
Hans-Christian Militzer
Hartwig Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43984137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2832123(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of CA2832123A1 publication Critical patent/CA2832123A1/en
Application granted granted Critical
Publication of CA2832123C publication Critical patent/CA2832123C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2832123A 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts Active CA2832123C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP11161111.7 2011-04-05
PCT/EP2012/055600 WO2012136553A1 (en) 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Publications (2)

Publication Number Publication Date
CA2832123A1 CA2832123A1 (en) 2012-10-11
CA2832123C true CA2832123C (en) 2018-09-11

Family

ID=43984137

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2832123A Active CA2832123C (en) 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Country Status (42)

Country Link
US (2) US10383876B2 (cg-RX-API-DMAC7.html)
EP (2) EP2508525A1 (cg-RX-API-DMAC7.html)
JP (2) JP5763834B2 (cg-RX-API-DMAC7.html)
KR (1) KR101937501B1 (cg-RX-API-DMAC7.html)
CN (1) CN103649091B (cg-RX-API-DMAC7.html)
AP (1) AP3709A (cg-RX-API-DMAC7.html)
AR (1) AR085718A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012238891B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013025549A2 (cg-RX-API-DMAC7.html)
CA (1) CA2832123C (cg-RX-API-DMAC7.html)
CL (1) CL2013002870A1 (cg-RX-API-DMAC7.html)
CO (1) CO6781534A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130511A (cg-RX-API-DMAC7.html)
CU (1) CU24208B1 (cg-RX-API-DMAC7.html)
CY (1) CY1116231T1 (cg-RX-API-DMAC7.html)
DK (1) DK2694508T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2013000223A (cg-RX-API-DMAC7.html)
EA (1) EA023646B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13013006A (cg-RX-API-DMAC7.html)
ES (1) ES2529653T3 (cg-RX-API-DMAC7.html)
GT (1) GT201300234A (cg-RX-API-DMAC7.html)
HR (1) HRP20150138T1 (cg-RX-API-DMAC7.html)
IL (1) IL228561A (cg-RX-API-DMAC7.html)
JO (1) JO2958B1 (cg-RX-API-DMAC7.html)
MA (1) MA35014B1 (cg-RX-API-DMAC7.html)
ME (1) ME02021B (cg-RX-API-DMAC7.html)
MX (1) MX336057B (cg-RX-API-DMAC7.html)
MY (1) MY169452A (cg-RX-API-DMAC7.html)
PE (1) PE20141038A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013502065A1 (cg-RX-API-DMAC7.html)
PL (1) PL2694508T3 (cg-RX-API-DMAC7.html)
PT (1) PT2694508E (cg-RX-API-DMAC7.html)
RS (1) RS53811B1 (cg-RX-API-DMAC7.html)
SG (1) SG193595A1 (cg-RX-API-DMAC7.html)
SI (1) SI2694508T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500037B (cg-RX-API-DMAC7.html)
TN (1) TN2013000401A1 (cg-RX-API-DMAC7.html)
TW (2) TWI592158B (cg-RX-API-DMAC7.html)
UA (1) UA111604C2 (cg-RX-API-DMAC7.html)
UY (1) UY33985A (cg-RX-API-DMAC7.html)
WO (1) WO2012136553A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307105B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
KR20160019434A (ko) 2013-06-14 2016-02-19 바이엘 파마 악티엔게젤샤프트 항-tweakr 항체 및 그의 용도
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EA201791974A1 (ru) * 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
JP6815329B2 (ja) 2015-03-23 2021-01-20 バイエル ファーマ アクチエンゲゼルシャフト 抗ceacam6抗体およびその使用
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
TN2018000271A1 (en) 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers.
TN2018000272A1 (en) 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
AU2017376766A1 (en) 2016-12-14 2019-06-06 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
CA3054249A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2019048527A1 (en) 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft COPANLISIB FORMULATIONS
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
JP2022505325A (ja) * 2018-10-17 2022-01-14 サンド・アクチエンゲゼルシヤフト レボチロキシン及びジカルボン酸を含む共結晶
US12139491B2 (en) * 2018-12-27 2024-11-12 Holosmedic Diketopiperazine derivatives as calcium ATPase inhibitor for enhancing anticancer activity
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts
WO2025053315A1 (ko) * 2023-09-08 2025-03-13 파로스젠 주식회사 항암제 프로드러그 컨쥬게이트의 제조에서 팔라듐의 회수 및 제거 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605550A5 (cg-RX-API-DMAC7.html) 1972-06-08 1978-09-29 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
WO2004029055A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2713388C (en) 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
EA201201414A8 (ru) 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
AP2015008750A0 (en) * 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
CN105934256B (zh) 2013-12-03 2019-12-27 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин

Also Published As

Publication number Publication date
ECSP13013006A (es) 2013-12-31
DOP2013000223A (es) 2013-11-15
SI2694508T1 (sl) 2015-03-31
EA023646B1 (ru) 2016-06-30
CN103649091B (zh) 2016-06-22
CY1116231T1 (el) 2017-02-08
JP5763834B2 (ja) 2015-08-12
US20160193219A1 (en) 2016-07-07
JO2958B1 (en) 2016-03-15
NZ616198A (en) 2015-09-25
UY33985A (es) 2012-10-31
TN2013000401A1 (en) 2015-03-30
CN103649091A (zh) 2014-03-19
TW201249847A (en) 2012-12-16
ME02021B (me) 2015-05-20
IL228561A (en) 2015-10-29
EA201391470A1 (ru) 2014-03-31
CR20130511A (es) 2013-12-04
MX336057B (es) 2016-01-07
CU20130133A7 (es) 2014-01-29
US20140072529A1 (en) 2014-03-13
EP2694508A1 (en) 2014-02-12
ES2529653T3 (es) 2015-02-24
CU24208B1 (es) 2016-11-29
PH12013502065A1 (en) 2016-06-29
TWI592158B (zh) 2017-07-21
CA2832123A1 (en) 2012-10-11
IL228561A0 (en) 2013-12-31
RS53811B1 (sr) 2015-06-30
WO2012136553A1 (en) 2012-10-11
EP2508525A1 (en) 2012-10-10
AU2012238891A1 (en) 2013-10-24
HRP20150138T1 (hr) 2015-05-08
UA111604C2 (uk) 2016-05-25
MA35014B1 (fr) 2014-04-03
US9636344B2 (en) 2017-05-02
JP2015164936A (ja) 2015-09-17
HK1195907A1 (zh) 2014-11-28
AP3709A (en) 2016-05-31
US10383876B2 (en) 2019-08-20
KR101937501B1 (ko) 2019-01-10
TWI549954B (zh) 2016-09-21
DK2694508T3 (en) 2015-02-16
EP2694508B1 (en) 2014-11-19
BR112013025549A2 (pt) 2016-12-27
SG193595A1 (en) 2013-10-30
PE20141038A1 (es) 2014-09-05
PT2694508E (pt) 2015-02-10
CL2013002870A1 (es) 2014-06-20
ZA201307105B (en) 2014-11-26
PL2694508T3 (pl) 2015-04-30
AP2013007219A0 (en) 2013-10-31
SMT201500037B (it) 2015-05-05
TW201637656A (zh) 2016-11-01
AU2012238891B2 (en) 2016-12-01
AR085718A1 (es) 2013-10-23
JP5826961B2 (ja) 2015-12-02
MY169452A (en) 2019-04-11
GT201300234A (es) 2015-01-16
CO6781534A2 (es) 2013-10-31
JP2014510119A (ja) 2014-04-24
KR20140021637A (ko) 2014-02-20
MX2013011583A (es) 2013-12-16

Similar Documents

Publication Publication Date Title
US9636344B2 (en) Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
US8138336B2 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
CA2837630A1 (en) Substituted aminoimidazopyridazines
JP2015537017A (ja) アミノイミダゾピリダジン類
TW201437211A (zh) 經取代咪唑并嗒□
CA2936024A1 (en) Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
US20180022750A1 (en) 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl-substituted imidazopyridazines
NZ616198B2 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
HK1239665A1 (en) 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl-substituted imidazopyridazines
NZ622129B2 (en) Amino-substituted imidazopyridazines

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170328

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20251002

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251107